SOLANA BEACH, Calif., October 26, 2021 (GLOBE NEWSWIRE) – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy platform company providing navigation and delivery to the brain, today announced that it will release its financial results for its third quarter 2021 on Tuesday, November 9, 2021, after market close.
Investors and analysts are invited to listen to a live review of the Company’s third quarter 2021 on Tuesday, November 9, 2021 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific time) which can be viewed online here. Investors and analysts who wish to participate in the conference call by telephone can do so at (888) 428-7458 or (862) 298-0702 if calling from outside the United States or Canada.
For those who cannot access the live stream, a replay will be available shortly after the call ends until December 9, 2021, by calling (877) 660-6853 or (201) 612- 7415 if calling from outside the United States or Canada, then entering the conference ID number 413671. An online archive of the broadcast will be available on the company’s investor website at https://ir.clearpointneuro.com/
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore the quality of life for patients and their families by enabling therapies for the most complex neurological disorders with pinpoint precision. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neurosuction, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint® Neuro navigation system has FDA clearance, is CE marked, and is installed at over 60 active sites in the United States, Canada and Europe. ClearPoint Neuro partners with more than 35 biologic / pharmaceutical companies and academic centers, providing solutions for the direct delivery of therapeutics to the CNS in preclinical studies and clinical trials around the world. To date, over 4,500 cases have been completed and managed by the Company’s team of clinical specialists in the field, who provide support and services to our clients and partners. For more information, please visit www.clearpointneuro.com.
Statements contained herein concerning the plans, growth and strategies of the Company may include forward-looking statements in the context of federal securities laws. Statements regarding future events, future developments and performance of the Company, as well as management’s expectations, beliefs, plans, estimates or projections regarding the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the actual results of the Company to differ materially from those expressed or implied by forward-looking statements. Uncertainties and particular risks include those related to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, market and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these factors and other factors that may affect the actual results of the company are described in the “Risk factors” section of the annual report of the company on Form 10-K for the year ended 31 December 2020, and in the company’s quarterly report on form. 10-Q for the quarter ended June 30, 2021, both filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, which the Company has intends to file with the Securities and Exchange Commission no later than November 15, 2021.
Danilo D’Alessandro, Chief Financial Officer
Caroline Corner, Investor Relations